The term LIPI Activators, referring to activators of lipase I, falls within a specialized category of biochemical compounds. Lipase I, a type of enzyme, plays a critical role in the biochemical process of lipid metabolism, specifically in the hydrolysis of fats into fatty acids and glycerol. Activators of lipase I are therefore compounds that enhance the enzymatic activity of this particular lipase. These activators work by binding to the enzyme, often at specific allosteric sites, thereby inducing a conformational change that increases the enzyme's catalytic efficiency. The molecular structure of these activators is typically characterized by specific functional groups or regions that are complementary to the binding sites on the lipase I enzyme, ensuring a high degree of specificity and efficacy in the activation process.
The development and study of LIPI Activators involve intricate processes in both synthetic chemistry and enzymology. Synthetic chemists design and create a diverse array of compounds, guided by the known structure and active sites of lipase I. This process often involves iterative cycles of synthesis and testing, refining the molecular structure of the activators to achieve optimal interaction with the enzyme. Concurrently, enzymologists and biochemists study the interaction between these activators and lipase I using various biochemical assays. Techniques such as enzyme kinetics analysis are pivotal in understanding how these compounds affect the rate of lipid hydrolysis catalyzed by lipase I. Moreover, structural biology techniques, like X-ray crystallography or NMR spectroscopy, are employed to elucidate the molecular details of the interaction between the activator and the enzyme. This detailed understanding aids in the rational design of more effective LIPI Activators, enhancing our comprehension of enzyme regulation and lipid metabolism at the molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
A known activator of protein kinase C (PKC) that may enhance the transcription of genes involved in lipid metabolism, potentially including LIPI. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that may upregulate genes by altering epigenetic marks, potentially affecting LIPI expression. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
A compound that activates peroxisome proliferator-activated receptor alpha (PPARα), potentially increasing the transcription of lipase-related genes. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
A synthetic PPARα agonist that could induce the expression of genes involved in fatty acid catabolism, including potentially LIPI. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
A PPARγ agonist that may indirectly influence lipase gene expression through effects on lipid homeostasis. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
A metabolite of vitamin A that can modulate gene expression, potentially affecting LIPI as part of lipid metabolism regulation. | ||||||
SRT1720 | 1001645-58-4 | sc-364624 sc-364624A | 5 mg 10 mg | $197.00 $364.00 | 13 | |
A Sirt1 activator that could influence the expression of genes related to lipid metabolism, potentially including LIPI. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
A secondary messenger that may upregulate genes through PKA signaling, potentially affecting LIPI expression. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
An HMG-CoA reductase inhibitor that might indirectly upregulate lipase gene expression due to its role in lipid metabolism. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Another PPARγ agonist that could have indirect effects on lipase gene expression, potentially including LIPI. | ||||||